National Health (Minimum Stockholding) Determination 2023

PB 65 of 2023

made under subsection 99AEKC(2) of the

National Health Act 1953

Compilation No. 31

Compilation date: 1 April 2026

Includes amendments: F2025L01310 and F2026L00379

Prepared by the Office of Parliamentary Counsel, Canberra

Authorised Version F2026C00359 registered 24/04/2026

About this compilation

This compilation

This is a compilation of the *National Health (Minimum Stockholding) Determination 2023* that shows the text of the law as amended and in force on 1 April 2026 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).

Application, saving and transitional provisions

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Presentational changes

The *Legislation Act 2003* provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1 Name 1
3 Authority 1
4 Definitions....1
5 Usual PBS demand....1

Part 2—Minimum stockholding requirement 3

6 Applicable quantity of a brand of a pharmaceutical item 3

Schedule 1—Applicable quantity of a brand of a pharmaceutical item 4

Endnotes 49

Endnote 1—About the endnotes 49

Endnote 2—Abbreviation key 50

Endnote 3—Legislation history 51

Endnote 4—Amendment history 55

Authorised Version F2026C00359 registered 24/04/2026

Authorised Version F2026C00359 registered 24/04/2026

Part 1—Preliminary

1 Name

(1) This instrument is the *National Health (Minimum Stockholding) Determination 2023*.

(2) This instrument may also be cited as PB 65 of 2023.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Definitions

In this instrument:

Act means the *National Health Act 1953*.

brand has the same meaning as in Part VII of the Act.

data collection period has the same meaning as in the *National Health (Pharmaceutical Benefits) Regulations 2017*.

pharmaceutical benefit has the same meaning as in Part VII of the Act.

pharmaceutical item has the same meaning as in Part VII of the Act.

pricing quantity has the same meaning as in Part VII of the Act.

usual demand, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.

usual PBS demand, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.

5 Usual PBS demand

(1) The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (***the reference period***) before the previous data collection period for the brand divided by the number of months in the reference period.

(2) For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:

Authorised Version F2026C00359 registered 24/04/2026

(a) the number of packs of the brand supplied as pharmaceutical benefits during that period; and

(b) adjusted as if the size of the pack equals the pricing quantity of the brand.

(3) For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.

Authorised Version F2026C00359 registered 24/04/2026

Part 2—Minimum stockholding requirement

6 Applicable quantity of a brand of a pharmaceutical item

For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1—Applicable quantity of a brand of a pharmaceutical item

Note: See section 6.

Applicable quantity of a brand of a pharmaceutical item

Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Acarbose	Tablet 100 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
Acarbose	Tablet 50 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
Aciclovir	Tablet 200 mg	Oral	ARX-ACICLOVIR	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together
Aciclovir	Tablet 800 mg	Oral	ARX-ACICLOVIR	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together
Allopurinol	Tablet 100 mg	Oral	Allosig	3 months stock by reference to usual demand
Allopurinol	Tablet 100 mg	Oral	APO-ALLOPURINOL	4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together
Allopurinol	Tablet 100 mg	Oral	Zyloprim	3 months stock by reference to usual demand
Allopurinol	Tablet 300 mg	Oral	APO-ALLOPURINOL	6 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together
Allopurinol	Tablet 300 mg	Oral	NOUMED ALLOPURINOL	between 1 April 2026 to 30 September 2026—0 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Allopurinol	Tablet 300 mg	Oral	Zyloprim	4 months stock by reference to usual demand
Amino acid formula with vitamins and minerals without phenylalanine	Oral gel 85 g, 30 (PKU squeezie)	Oral	PKU squeezie	0 months stock by reference to usual PBS demand
Amisulpride	Oral solution 100 mg per mL, 60 mL	Oral	Solian Solution	4 months stock by reference to usual PBS demand
Amisulpride	Tablet 100 mg	Oral	AMISULPRIDE-WGR	between 1 December 2025 to 30 April 2026— 0 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 10 mg	Oral	ENTRIP	4 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	APX-Amitriptyline	5 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	ENTRIP	4 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	APX-Amitriptyline	4.5 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	ENTRIP	4.5 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Amlodipine	Tablet 10 mg (as besilate)	Oral	APX-AMLODIPINE	6 months stock by reference to usual demand of both APX-AMLODIPINE and Amlodipine APOTEX added together
Amlodipine	Tablet 5 mg (as besilate)	Oral	APX-AMLODIPINE	6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together
Amoxicillin	Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL	Oral	Amoxil	4 months stock by reference to usual PBS demand
Amoxicillin	Capsule 250 mg (as trihydrate)	Oral	Amoxil	between 1 April 2026 to 31 August 2026—0 months stock by reference to usual demand
Amoxicillin with clavulanic acid	Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Alphaclav Duo Viatris	after 31 December 2025—6 months stock by reference to usual demand of both Alphaclav Duo Viatris and AlphaClav Duo added together
Amoxicillin with clavulanic acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	AlphaClav Duo Forte Viatris	6 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Amphotericin B	Lozenge 10 mg	Oral	Fungilin	4 months stock by reference to usual PBS demand
Anakinra	Injection 100 mg in 0.67 mL single use pre-filled syringe	Injection	Kineret	6 months stock by reference to usual PBS demand
Aripiprazole	Tablet 10 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Aripiprazole	Tablet 15 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Aripiprazole	Tablet 20 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Aripiprazole	Tablet 30 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Atazanavir	Capsule 200 mg (as sulfate)	Oral	Reyataz	between 1 October 2025 to 30 June 2026—0 months stock by reference to usual demand
Atazanavir	Capsule 300 mg (as sulfate)	Oral	Reyataz	between 1 October 2025 to 30 June 2026—0 months stock by reference to usual demand
Atenolol	Oral solution 50 mg in 10 ml, 300 ml	Oral	Atenolol-AFT	(a) between 1 January 2025 and 31 May 2025—4 months stock by reference to usual PBS demand (b) after 31 May 2025—6 months stock by reference to usual PBS demand
Atenolol	Tablet 50 mg	Oral	APX-Atenolol	4 months stock by reference to usual demand
Atenolol	Tablet 50 mg	Oral	Tensig	4 months stock by reference to usual demand
Atomoxetine	Capsule 10 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Atomoxetine	Capsule 100 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 18 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 25 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 40 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 60 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 80 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atropine	Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL	Injection	Atropine Injection (Bridgewest)	(a) between 1 April 2025 and 30 September 2025—6 months stock by reference to usual PBS demand of Atropine Injection (Pfizer) (b) between 1 October 2025 and 31 March 2026—6 months stock by reference to usual PBS demand of both Atropine Injection (Pfizer) and Atropine Injection (Bridgewest) added together (c) after 31 March 2026—6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Azithromycin	Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL	Oral	Zithromax	4 months stock by reference to usual PBS demand
Baclofen	Tablet 10 mg	Oral	APO-Baclofen	3 months stock by reference to usual demand
Balsalazide	Capsule containing balsalazide sodium 750 mg	Oral	Colazide	6 months stock by reference to usual PBS demand
Benzathine benzylpenicillin	Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
Benzathine benzylpenicillin	Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
Bivalirudin	Powder for I.V. injection 250 mg (as trifluoroacetate)	Injection	BIVALIRUDIN ARX	4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Bleomycin	Powder for injection containing bleomycin sulfate 15,000 I.U.	Injection	DBL Bleomycin Sulfate	between 1 February 2026 and 31 July 2026—4 months stock by reference to usual demand
Bosentan	Tablet 125 mg (as monohydrate)	Oral	Bosentan APO	3 months stock by reference to usual demand
Budesonide	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	Inhalation	Pulmicort Respules	(a) between 1 October 2025 and 31 March 2026—7,770 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand
Budesonide	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by Mouth	Pulmicort Turbuhaler	(a) between 1 October 2025 and 31 March 2026—31,080 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand
Calcium	Tablet 600 mg (as carbonate)	Oral	Calci-Tab 600	6 months stock by reference to usual PBS demand
Calcium	Tablet, chewable, 500 mg (as carbonate)	Oral	Cal-500	6 months stock by reference to usual PBS demand
Captopril	Oral solution 5 mg per mL, 95 mL	Oral	Capoten	4 months stock by reference to usual PBS demand
Carboplatin	Solution for I.V. injection 450 mg in 45 mL	Injection	Carboplatin Accord	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Cefalexin	Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL	Oral	Keflex	between 1 February 2026 and 31 July 2026—0 months stock by reference to usual demand
Cefazolin	Powder for injection 1 g (as sodium)	Injection	Cefazolin-AFT	300,000 packs of a pack quantity of 5
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cephazolin Viatris	6 months stock by reference to usual demand
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone Viatris	6 months stock by reference to usual demand
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viatris	6 months stock by reference to usual demand
Chloramphenicol	Eye drops 5 mg per mL, 10 mL	Application to the Eye	Chlorsig	4 months stock by reference to usual PBS demand
Chlorpromazine	Injection containing chlorpromazine hydrochloride 50 mg in 2 mL	Injection	Largactil	6 months stock by reference to usual PBS demand
Chlorpromazine	Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL	Oral	Largactil	6 months stock by reference to usual PBS demand
Chlorpromazine	Tablet containing chlorpromazine hydrochloride 100 mg	Oral	Largactil	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Chlorpromazine	Tablet containing chlorpromazine hydrochloride 25 mg	Oral	Largactil	6 months stock by reference to usual PBS demand
Chlortalidone	Tablet 25 mg	Oral	Hygroton 25	4 months stock by reference to usual PBS demand
Choriogonadotropin alfa	Solution for injection 250 micrograms in 0.5 mL pre-filled pen	Injection	Ovidrel	6 months stock by reference to usual PBS demand
Ciclosporin	Capsule 10 mg	Oral	Neoral 10	4 months stock by reference to usual PBS demand
Ciclosporin	Capsule 100 mg	Oral	APO-Ciclosporin	2.5 months stock by reference to usual demand
Ciclosporin	Capsule 25 mg	Oral	APO-Ciclosporin	3 months stock by reference to usual demand
Ciclosporin	Capsule 50 mg	Oral	APO-Ciclosporin	3 months stock by reference to usual demand
Ciclosporin	Oral liquid 100 mg per mL, 50 mL	Oral	Neoral	4 months stock by reference to usual PBS demand
Ciprofloxacin	Ear drops 3 mg (as hydrochloride) per mL, 5 mL	Application to the Ear	Ciloxan	6 months stock by reference to usual PBS demand
Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL	Oral	Klacid	(a) between 1 April 2025 and 30 September 2025—17,180 packs of a pack quantity of 1 (b) after 30 September 2025—4 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Clonazepam	Oral liquid 2.5 mg per mL, 10 mL	Oral	Rivotril	6 months stock by reference to usual PBS demand
Codeine	Tablet containing codeine phosphate hemihydrate 30 mg	Oral	Aspen Pharmacare Australia Pty Ltd	4 months stock by reference to usual PBS demand
Dantrolene	Capsule containing dantrolene sodium hemiheptahydrate 25 mg	Oral	Dantrium	6 months stock by reference to usual PBS demand
Diazepam	Oral liquid 10 mg per 10 mL, 100 mL	Oral	Diazepam Elixir	(a) between 1 April 2025 and 30 September 2025—1,228 packs of a pack quantity of 1 (b) after 30 September 2025—4 months stock by reference to usual PBS demand
Diphtheria and tetanus vaccine, adsorbed, diluted for adult use	Injection 0.5 mL in pre-filled syringe	Injection	ADT Booster	6 months stock by reference to usual PBS demand
Dolutegravir with abacavir and lamivudine	Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg	Oral	Triumeq	6 months stock by reference to usual PBS demand
Dosulepin	Capsule containing dosulepin hydrochloride 25 mg	Oral	Dosulepin Viatris	6 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Doxorubicin	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial	Injection/Intravesical	Doxorubicin ACC	between 1 February 2026 and 31 July 2026—4 months stock by reference to usual demand
Doxorubicin	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial	Injection/Intravesical	Adriamycin	between 1 February 2026 and 31 July 2026—4 months stock by reference to usual demand
Doxorubicin - pegylated liposomal	Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL	Injection	Liposomal Doxorubicin SUN	3 months stock by reference to usual demand
Doxorubicin - pegylated liposomal	Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL	Injection	Liposomal Doxorubicin SUN	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Doxycycline	Capsule 100 mg (as hyclate) (containing enteric coated pellets)	Oral	Doryx	4 months stock by reference to usual demand
Doxycycline	Capsule 50 mg (as hyclate) (containing enteric coated pellets)	Oral	Doryx	4 months stock by reference to usual demand
Doxycycline	Tablet 100 mg (as hyclate)	Oral	APX-Doxycycline	5.5 months stock by reference to usual demand
Doxycycline	Tablet 50 mg (as hyclate)	Oral	Doxsig	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	APO-Enalapril	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	Malean	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 20 mg	Oral	APO-Enalapril	3 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 20 mg	Oral	Malean	3 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Acetec	2 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	APO-Enalapril	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Malean	4 months stock by reference to usual demand
Erlotinib	Tablet 100 mg (as hydrochloride)	Oral	Erlotinib APOTEX	4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 100 mg (as hydrochloride)	Oral	ERLOTINIB ARX	after 28 February 2026—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 150 mg (as hydrochloride)	Oral	Erlotinib APOTEX	after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 150 mg (as hydrochloride)	Oral	ERLOTINIB ARX	after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 25 mg (as hydrochloride)	Oral	Erlotinib APOTEX	4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 25 mg (as hydrochloride)	Oral	ERLOTINIB ARX	4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Erythromycin	Capsule 250 mg (containing enteric coated pellets)	Oral	Mayne Pharma Erythromycin	2 months stock by reference to usual demand
Escitalopram	Oral solution 20 mg (as oxalate) per mL, 15 mL	Oral	Lexapro	4 months stock by reference to usual PBS demand
Escitalopram	Tablet 10 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
Escitalopram	Tablet 20 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
Estradiol and estradiol with norethisterone	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate	Transdermal	Estalis sequi 50/140	6 months stock by reference to usual PBS demand
Estradiol with norethisterone	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8	Transdermal	Estalis continuous 50/140	6 months stock by reference to usual PBS demand
Ezetimibe with atorvastatin	Tablet 10 mg-10 mg	Oral	Atozet	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Ezetimibe with atorvastatin	Tablet 10 mg-10 mg	Oral	Ezetast	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Ezetimibe with atorvastatin	Tablet 10 mg-10 mg	Oral	Ezetimibe/Atorvastatin GH 10/10	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Ezetimibe with atorvastatin	Tablet 10 mg-20 mg	Oral	Atozet	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Ezetimibe with atorvastatin	Tablet 10 mg-20 mg	Oral	Ezetast	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Ezetimibe with atorvastatin	Tablet 10 mg-20 mg	Oral	Ezetimibe/Atorvastatin GH 10/20	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	APO-Ezetimibe/Simvastatin 10/10	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	APO-Ezetimibe/Simvastatin 10/20	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	APO-Ezetimibe/Simvastatin 10/40	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	APO-Ezetimibe/Simvastatin 10/80	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Felodipine	Tablet 2.5 mg (extended release)	Oral	Felodur ER 2.5 mg	2.5 months stock by reference to usual demand
Felodipine	Tablet 2.5 mg (extended release)	Oral	Plendil ER	2.5 months stock by reference to usual demand
Fenofibrate	Tablet 48 mg	Oral	FENOFIBRATE CIPLA	between 1 February 2026 and 30 April 2026—0 months stock by reference to usual demand
Fentanyl	Transdermal patch 12.6 mg	Transdermal	Fentanyl Sandoz	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Fentanyl	Transdermal patch 12.6 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
Fentanyl	Transdermal patch 16.8 mg	Transdermal	Fentanyl Sandoz	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Fentanyl	Transdermal patch 16.8 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
Fentanyl	Transdermal patch 2.1 mg	Transdermal	APO-Fentanyl	3.5 months stock by reference to usual demand
Fentanyl	Transdermal patch 2.1 mg	Transdermal	Fentanyl Sandoz	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Fentanyl	Transdermal patch 4.2 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
Fentanyl	Transdermal patch 4.2 mg	Transdermal	Fentanyl Sandoz	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Fentanyl	Transdermal patch 8.4 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Fentanyl	Transdermal patch 8.4 mg	Transdermal	Fentanyl Sandoz	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Ferrous Sulfate	Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL	Oral	Ferro-Liquid	6 months stock by reference to usual PBS demand
Fluconazole	Capsule 200 mg	Oral	APO-Fluconazole	4 months stock by reference to usual demand of both Fluconazole APOTEX and APO-Fluconazole added together
Fluconazole	Powder for oral suspension 50 mg in 5 mL, 35 mL	Oral	Diflucan	4 months stock by reference to usual PBS demand
Fludarabine	Powder for I.V. injection containing fludarabine phosphate 50 mg	Injection	Fludarabine Juno	between 1 February 2026 and 31 July 2026—4 months stock by reference to usual demand
Fludarabine	Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL	Injection	Fludarabine Ebewe	between 1 February 2026 and 31 July 2026—4 months stock by reference to usual demand
Folic acid	Tablet 5 mg	Oral	Megafol 5	4 months stock by reference to usual PBS demand
Folic acid	Tablet 500 micrograms	Oral	Foltabs 500	4 months stock by reference to usual PBS demand
Folic acid	Tablet 500 micrograms	Oral	Megafol 0.5	4 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Folinic acid	Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL	Injection	Leucovorin Calcium (Pfizer Australia Pty Ltd)	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Fosinopril	Tablet containing fosinopril sodium 10 mg	Oral	APO-Fosinopril	3 months stock by reference to usual demand
Fosinopril	Tablet containing fosinopril sodium 20 mg	Oral	APO-Fosinopril	3 months stock by reference to usual demand
Framycetin	Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL	Application to the Eye/Ear	Soframycin	4 months stock by reference to usual PBS demand
Furosemide	Oral solution 10 mg per ml, 30 ml	Oral	Lasix	(a) between 1 November 2024 and 31 March 2025—4 months stock by reference to usual PBS demand (b) after 31 March 2025—6 months stock by reference to usual PBS demand
Fusidic acid	Tablet containing sodium fusidate 250 mg	Oral	Fucidin	6 months stock by reference to usual PBS demand
Gabapentin	Capsule 400 mg	Oral	GAPENTIN	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Gabapentin	Tablet 600 mg	Oral	APX-GABAPENTIN	4 months stock by reference to usual demand of both Gabapentin APOTEX and APX-GABAPENTIN added together
Galantamine	Capsule (prolonged release) 16 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 24 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Galantyl	1.5 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
Glimepiride	Tablet 1 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 2 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Glimepiride	Tablet 3 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 3 mg	Oral	GLIMEPIRIDE-WGR	between 1 March 2026 to 31 August 2026— 0 months stock by reference to usual demand
Glimepiride	Tablet 4 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glucose and ketone indicator-urine	Test strips, 50 (Keto-Diastix)	For External Use	Keto-Diastix	4 months stock by reference to usual PBS demand
Glyceryl trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses	Sublingual	Nitrolingual Pumpspray	(a) between 1 August 2025 and 30 September 2025—108,288 packs of a pack quantity of 1 (b) between 1 October 2025 and 31 March 2026—109,488 packs of a pack quantity of 1 (c) after 31 March 2026—4 months stock by reference to usual PBS demand
Glycomacropeptide and essential amino acids with vitamins and minerals	Bars 81 g, 7 (Camino Pro Complete)	Oral	Camino Pro Complete	6 months stock by reference to usual PBS demand
Glycomacropeptide and essential amino acids with vitamins and minerals	Oral liquid 250 mL, 30 (PKU Glytactin RTD 15 Lite)	Oral	PKU Glytactin RTD 15 Lite	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Glycomacropeptide and essential amino acids with vitamins and minerals	Oral liquid 250 mL, 30 (PKU Glytactin RTD 15)	Oral	PKU Glytactin RTD 15	6 months stock by reference to usual PBS demand
Glycomacropeptide and essential amino acids with vitamins and minerals	Sachets containing oral powder 15 g, 30 (PKU Build 10)	Oral	PKU Build 10	6 months stock by reference to usual PBS demand
Glycomacropeptide and essential amino acids with vitamins and minerals	Sachets containing oral powder 32 g, 30 (PKU Build 20)	Oral	PKU Build 20	6 months stock by reference to usual PBS demand
Glycomacropeptide and essential amino acids with vitamins and minerals	Sachets containing oral powder 40 g, 30 (Camino Pro Bettermilk)	Oral	Camino Pro Bettermilk	6 months stock by reference to usual PBS demand
Haloperidol	Tablet 1.5 mg	Oral	Serenace	4 months stock by reference to usual PBS demand
Haloperidol	Tablet 5 mg	Oral	Serenace	4 months stock by reference to usual PBS demand
Haloperidol	Tablet 500 micrograms	Oral	Serenace	4 months stock by reference to usual PBS demand
Heparin	Injection 5,000 units (as sodium) in 0.2 ml	Injection	DBL Heparin Sodium	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate	Oral liquid 250 mL, 30 (KetoVie 3:1)	Oral	KetoVie 3:1	6 months stock by reference to usual PBS demand
High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate	Oral liquid 250 mL, 30 (KetoVie 4:1)	Oral	KetoVie 4:1	6 months stock by reference to usual PBS demand
High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate	Oral liquid 250 mL, 30 (KetoVie Peptide 4:1)	Oral	KetoVie Peptide 4:1	6 months stock by reference to usual PBS demand
Imatinib	Capsule 100 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together
Imatinib	Capsule 400 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together
Indapamide	Tablet containing indapamide hemihydrate 2.5 mg	Oral	Insig	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Insect allergen extract-honey bee venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Honey Bee Venom	6 months stock by reference to usual PBS demand
Insect allergen extract-paper wasp venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Paper Wasp Venom	6 months stock by reference to usual PBS demand
Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms	Injection	Albey Yellow Jacket Venom	6 months stock by reference to usual PBS demand of Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms with diluent, Injection (Hymenoptera Yellow Jacket Venom) and Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms, Injection (Albey Yellow Jacket Venom)
Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	AVSARTAN HCT 150/12.5	4 months stock by reference to usual demand
Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000)	Oral	Isoleucine 1000	0 months stock by reference to usual PBS demand
Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)	Oral	Isoleucine 50	0 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Lamivudine	Tablet 150 mg	Oral	Lamivudine Viatris	after 30 September 2025—4 months stock by reference to usual demand of both Lamivudine Viatris and Lamivudine Alphapharm added together
Lansoprazole	Tablet 15 mg (orally disintegrating)	Oral	APO-Lansoprazole ODT	4.5 months stock by reference to usual demand
Lansoprazole	Tablet 30 mg (orally disintegrating)	Oral	APO-Lansoprazole ODT	3 months stock by reference to usual demand
Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	Application to the Eye	APO-Latanoprost	2 months stock by reference to usual demand
Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	Application to the Eye	APO-Latanoprost/Timolol 0.05/5	2.5 months stock by reference to usual demand
Leflunomide	Tablet 10 mg	Oral	APO-LEFLUNOMIDE	4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together
Leflunomide	Tablet 20 mg	Oral	APO-LEFLUNOMIDE	4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	Oral	ARX-LERCANIDIPINE	6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together
Lercanidipine	Tablet containing lercanidipine hydrochloride 20 mg	Oral	ARX-LERCANIDIPINE	6 months stock by reference to usual demand
Letrozole	Tablet 2.5 mg	Oral	ARX-LETROZOLE	4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together
Levetiracetam	Tablet 1 g	Oral	Levetiracetam Viatris	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together
Levetiracetam	Tablet 1 g	Oral	LEVETIRACETAM-WGR	6 months stock by reference to usual demand
Levetiracetam	Tablet 250 mg	Oral	Levetiracetam Viatris	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together
Levonorgestrel	Intrauterine drug delivery system 52 mg	Intrauterine	Mirena	6 months stock by reference to usual PBS demand
Lithium	Tablet containing lithium carbonate 250 mg	Oral	Lithicarb	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Lithium	Tablet containing lithium carbonate 450 mg (slow release)	Oral	Quilonum SR	6 months stock by reference to usual PBS demand
Meloxicam	Tablet 7.5 mg	Oral	MELOBIC	4 months stock by reference to usual demand
Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth	Penthrox (Combination Pack)	6 months stock by reference to usual PBS demand
Methylphenidate	Tablet containing methylphenidate hydrochloride 10 mg	Oral	Artige	between 1 January 2026 to 31 December 2026 - 3 months stock by reference to usual demand
Methylphenidate	Tablet containing methylphenidate hydrochloride 10 mg	Oral	Ritalin 10	between 1 January 2026 to 31 December 2026 - 3 months stock by reference to usual demand
Metoclopramide	Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL	Injection	Metoclopramide HCl Medsurge	6 months stock by reference to usual demand
Metoprolol	Tablet containing metoprolol tartrate 100 mg	Oral	Metrol 100	4 months stock by reference to usual demand
Metronidazole	Suppositories 500 mg, 10	Rectal	Flagyl	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Mifepristone and misoprostol	Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms	Oral	MS-2 Step	6 months stock by reference to usual PBS demand
Milk protein and fat formula with vitamins and minerals -- carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral	Carbohydrate Free Mixture	6 months stock by reference to usual PBS demand
Modafinil	Tablet 100 mg	Oral	Modafin	3 months stock by reference to usual demand
Modafinil	Tablet 100 mg	Oral	Modafinil Viatris	after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral	APX-Montelukast	4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral	Montelukast Viatris	after 31 July 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together
Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral	Montelukast Viatris	after 31 August 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	ARX-MYCOPHENOLATE	4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together
Nevirapine	Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL	Oral	Viramune	4 months stock by reference to usual PBS demand
Nicorandil	Tablets 10 mg, 60	Oral	APO-Nicorandil	2 months stock by reference to usual demand
Nicorandil	Tablets 10 mg, 60	Oral	Ikotab	2 months stock by reference to usual demand
Nicorandil	Tablets 20 mg, 60	Oral	APO-Nicorandil	2 months stock by reference to usual demand
Nicorandil	Tablets 20 mg, 60	Oral	Ikotab	2 months stock by reference to usual demand
Norfloxacin	Tablet 400 mg	Oral	APO-Norfloxacin	2.5 months stock by reference to usual demand
Olanzapine	Tablet 10 mg (orally disintegrating)	Oral	OLANZAPINE ODT-WGR	between 1 February 2026 and 31 July 2026—0 months stock by reference to usual demand
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	PRYZEX ODT	3.5 months stock by reference to usual demand
Olanzapine	Tablet 2.5 mg	Oral	APO-OLANZAPINE	6 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together
Olanzapine	Tablet 5 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	3 months stock by reference to usual demand
Olanzapine	Tablet 7.5 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together
Olanzapine	Tablet 20 mg (orally disintegrating)	Oral	OLANZAPINE ODT-WGR	between 1 March 2026 to 31 August 2026— 0 months stock by reference to usual demand
Olmesartan	Tablet containing olmesartan medoxomil 20 mg	Oral	OLMERTAN	3 months stock by reference to usual demand
Olmesartan	Tablet containing olmesartan medoxomil 40 mg	Oral	OLMERTAN	3.5 months stock by reference to usual demand
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	APO-OLMESARTAN/AMLODIPINE 20/5	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 20/5 mg added together
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	Oral	APO-OLMESARTAN/AMLODIPINE 40/10	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/10 added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	APO-OLMESARTAN/AMLODIPINE 40/5	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/5 mg added together
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	Oral	OLMERTAN COMBI 20/12.5	3 months stock by reference to usual demand
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	Oral	OLMERTAN COMBI 40/12.5	3 months stock by reference to usual demand
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	Oral	OLMERTAN COMBI 40/25	3 months stock by reference to usual demand
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral	Zofran syrup 50 mL	(a) between 1 October 2025 and 31 March 2026—2,204 packs of a pack quantity of 1 (b) after 31 March 2026—4 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	Ondansetron ODT Viatris	after 30 September 2025—6 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	Ondansetron ODT Viatris	after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together
Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viatris	after 31 May 2025—6 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together
Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viatris	after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together
Oxaliplatin	Solution concentrate for I.V. infusion 200 mg in 40 mL	Injection	Oxaliplatin SUN	between 1 March 2026 to 31 August 2026—0 months stock by reference to usual demand
Oxazepam	Tablet 30 mg	Oral	APO-Oxazepam	5.5 months stock by reference to usual demand
Oxazepam	Tablet 30 mg	Oral	Murelax	5 months stock by reference to usual demand
Oxybutynin	Transdermal patches 36 mg, 8	Transdermal	Oxytrol	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Oxycodone	Capsule containing oxycodone hydrochloride 10 mg	Oral	Oxycodone BNM	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Oxycodone	Capsule containing oxycodone hydrochloride 10 mg	Oral	OxyNorm	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Oxycodone	Capsule containing oxycodone hydrochloride 20 mg	Oral	Oxycodone BNM	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Oxycodone	Capsule containing oxycodone hydrochloride 20 mg	Oral	OxyNorm	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Oxycodone	Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL	Oral	OxyNorm Liquid 1mg/mL	4 months stock by reference to usual PBS demand
Pantoprazole	Sachet containing granules 40 mg (as sodium sesquihydrate)	Oral	Somac	4 months stock by reference to usual PBS demand
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APO-Pantoprazole	5.5 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Sozol	5.5 months stock by reference to usual demand
Pemetrexed	Powder for I.V. infusion 1 g (as disodium)	Injection	Pemetrexed Accord	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Pemetrexed	Powder for I.V. infusion 1 g (as disodium)	Injection	Pemetrexed SUN	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Periciazine	Tablet 10 mg	Oral	Neulactil	6 months stock by reference to usual PBS demand
Periciazine	Tablet 2.5 mg	Oral	Neulactil	6 months stock by reference to usual PBS demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Perindo Combi 4/1.25	2.5 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Permethrin	Cream 50 mg per g, 30 g	Application	Lyclear	(a) between 1 October 2025 and 31 March 2026—25,734 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand
Phenelzine	Tablet 15 mg (as sulfate)	Oral	Nardil	6 months stock by reference to usual PBS demand
Pimecrolimus	Cream 10 mg per g, 15 g	Application	Elidel	6 months stock by reference to usual PBS demand
Pioglitazone	Tablet 15 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Probenecid	Tablet 500 mg	Oral	Pro-Cid	6 months stock by reference to usual PBS demand
Prochlorperazine	Injection containing prochlorperazine mesilate 12.5 mg in 1 mL	Injection	Stemetil	6 months stock by reference to usual PBS demand
Promethazine	Injection containing promethazine hydrochloride 50 mg in 2 mL	Injection	DBL Promethazine Hydrochloride	6 months stock by reference to usual PBS demand
Propylene glycol	Eye drops 60 micrograms per mL, 10 mL	Application to the Eye	Systane Balance	4 months stock by reference to usual PBS demand
Protein hydrolysate formula with medium chain triglycerides	Oral powder 450 g (Aptamil Gold+ Pepti-Junior)	Oral	Aptamil Gold+ Pepti-Junior	6 months stock by reference to usual PBS demand
Quetiapine	Tablet 100 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quetiapine	Tablet 200 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quetiapine	Tablet 25 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Quetiapine	Tablet 300 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quinapril	Tablet 10 mg (as hydrochloride)	Oral	APO-Quinapril	3 months stock by reference to usual demand
Quinapril	Tablet 20 mg (as hydrochloride)	Oral	APO-Quinapril	3 months stock by reference to usual demand
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	Oral	APO-Rabeprazole	4 months stock by reference to usual demand
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	Oral	Parbezol	4 months stock by reference to usual demand
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	Oral	RALOVISTA	3 months stock by reference to usual demand
Ramipril	Capsule 10 mg	Oral	APX-Ramipril	5.5 months stock by reference to usual demand
Ramipril	Capsule 10 mg	Oral	Prilace	5.5 months stock by reference to usual demand
Ramipril	Tablet 1.25 mg	Oral	Prilace	2.5 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Ramipril	Tablet 1.25 mg	Oral	Ramipril Viatris	(a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25 (b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together
Ramipril	Tablet 10 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together
Ramipril	Tablet 2.5 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together
Ramipril	Tablet 5 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 5 added together
Risedronic acid	Tablet containing risedronate sodium 150 mg	Oral	APO-Risedronate	3 months stock by reference to usual demand
Risperidone	Tablet 3 mg	Oral	APO-Risperidone	3.5 months stock by reference to usual demand
Risperidone	Tablet 3 mg	Oral	Rispa	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	APO-RIZATRIPTAN ODT	4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together
Rosuvastatin	Tablet 10 mg (as calcium)	Oral	APO-Rosuvastatin	6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together
Rosuvastatin	Tablet 20 mg (as calcium)	Oral	APO-ROSUVASTATIN	4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin	Tablet 40 mg (as calcium)	Oral	APO-ROSUVASTATIN	4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	APO-ROSUVASTATIN	6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Roxithromycin	Tablet 150 mg	Oral	APX-Roxithromycin	4 months stock by reference to usual demand
Roxithromycin	Tablet 300 mg	Oral	APX-Roxithromycin	5 months stock by reference to usual demand
Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Salbutamol Cipla	between 1 April 2026 to 30 September 2026—0 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Asmol CFC-Free with dose counter	4 months stock by reference to usual demand
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Ventolin CFC-Free with dose counter	4 months stock by reference to usual demand
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Zempreon CFC-Free with dose counter	4 months stock by reference to usual demand
Sevelamer	Tablet containing sevelamer carbonate 800 mg	Oral	ARX-SEVELAMER	4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together
Sodium acid phosphate	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral	PHOSPHATE PHEBRA	6 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Sotalol	Tablet containing sotalol hydrochloride 160 mg	Oral	Cardol	1.5 months stock by reference to usual demand
Sumatriptan	Tablet 50 mg (as succinate)	Oral	APO-Sumatriptan	4 months stock by reference to usual demand
Tacrolimus	Capsule 1 mg	Oral	Tacrograf	3 months stock by reference to usual demand
Tacrolimus	Capsule 5 mg	Oral	Tacrograf	3 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 40 mg-10 mg (as besilate)	Oral	Pritor/Amlodipine	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 40 mg-10 mg (as besilate)	Oral	Twynsta	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 40 mg-5 mg (as besilate)	Oral	Pritor/Amlodipine	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 40 mg-5 mg (as besilate)	Oral	Twynsta	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 80 mg-10 mg (as besilate)	Oral	Pritor/Amlodipine	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 80 mg-10 mg (as besilate)	Oral	Twynsta	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Telmisartan with amlodipine	Tablet 80 mg-5 mg (as besilate)	Oral	Pritor/Amlodipine	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Telmisartan with amlodipine	Tablet 80 mg-5 mg (as besilate)	Oral	Twynsta	between 1 October 2025 to 31 January 2027— 0 months stock by reference to usual demand
Temazepam	Tablet 10 mg	Oral	APO-Temazepam	2.5 months stock by reference to usual demand
Temozolomide	Capsule 100 mg	Oral	Temodal	between 1 February 2026 and 31 July 2026—0 months stock by reference to usual demand
Temozolomide	Capsule 140 mg	Oral	Temodal	between 1 February 2026 and 31 July 2026—0 months stock by reference to usual demand
Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir ARX	4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	TENOFOVIR/EMTRICITABINE 300/200 APX	6 months stock by reference to usual demand
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	TENOFOVIR/EMTRICITABINE 300/200 ARX	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg	Oral	Tenofovir/Emtricitabine Sandoz 301/200	between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand
Terbinafine	Tablet 250 mg (as hydrochloride)	Oral	NOUMED TERBINAFINE	between 1 November 2025 to 30 April 2026—0 months stock by reference to usual demand
Thiamine	Tablet containing thiamine hydrochloride 100 mg	Oral	Betavit	4 months stock by reference to usual PBS demand
Tobramycin	Injection 80 mg (as sulfate) in 2 mL (without preservative)	Injection	Pfizer Australia Pty Ltd	2 months stock by reference to usual demand
Topiramate	Tablet 100 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Topiramate	Tablet 200 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Topiramate	Tablet 25 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Topiramate	Tablet 50 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Tramadol	Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL	Oral	Tramal	4 months stock by reference to usual PBS demand
Trandolapril	Capsule 1 mg	Oral	Dolapril 1	3 months stock by reference to usual demand
Trandolapril	Capsule 2 mg	Oral	Dolapril 2	3 months stock by reference to usual demand
Trandolapril	Capsule 4 mg	Oral	Dolapril 4	3 months stock by reference to usual demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	**Column 2 Form**	**Column 3 Manner of administration**	**Column 4 Brand**	**Column 5 Applicable quantity**
Trandolapril	Capsule 500 micrograms	Oral	Dolapril 0.5	2.5 months stock by reference to usual demand
Triglycerides—medium chain, formula	Oral powder 400 g (Lipistart)	Oral	Lipistart	0 months stock by reference to usual PBS demand
Triglycerides, long chain with glucose polymer	Oral liquid 1 L, 6 (ProZero)	Oral	ProZero	0 months stock by reference to usual PBS demand
Triglycerides, medium chain	Oil 500 ml (MCT Oil)	Oral	MCT Oil	6 months stock by reference to usual PBS demand
Trimethoprim	Tablet 300 mg	Oral	Trimethoprim Viatris	6 months stock by reference to usual demand
Valganciclovir	Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL	Oral	Valcyte	4 months stock by reference to usual PBS demand
Valine with carbohydrate	Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral	Valine 1000	0 months stock by reference to usual PBS demand
Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral	Valine 50	0 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Valproic acid	Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Liquid	(a) between 1 February 2025 and 31 March 2025—89,358 packs of a pack quantity of 1 (b) between 1 April 2025 and 30 September 2025—91,362 packs of a pack quantity of 1 (c) after 30 September 2025—6 months stock by reference to usual PBS demand
Valproic acid	Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Syrup	6 months stock by reference to usual PBS demand
Valproic acid	Tablet, crushable, containing sodium valproate 100 mg	Oral	Epilim	4 months stock by reference to usual PBS demand
Vancomycin	Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together
Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Juno	6 months stock by reference to usual demand
Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together

Authorised Version F2026C00359 registered 24/04/2026

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 **Drug**	**Column 2** **Form**	**Column 3** **Manner of administration**	**Column 4** **Brand**	**Column 5** **Applicable quantity**
Vincristine	I.V. injection containing vincristine sulfate 1 mg in 1 mL	Injection	DBL Vincristine	between 1 January 2026 to 28 February 2026—0 months stock by reference to usual demand
Voriconazole	Powder for oral suspension 40 mg per mL, 70 mL	Oral	Vfend	4 months stock by reference to usual PBS demand

Authorised Version F2026C00359 registered 24/04/2026

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history

Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes
The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and "(md not incorp)" is added to the amendment history.

Authorised Version F2026C00359 registered 24/04/2026

Endnote 2—Abbreviation key

ad = added or inserted

am = amended

amdt = amendment

C[x] = Compilation No. x

ch = Chapter(s)

cl = clause(s)

cont. = continued

def = definition(s)

Dict = Dictionary

disallowed = disallowed by Parliament

div = Division(s)

ed = editorial change

exp = expires/expired or ceases/ceased to have effect

gaz = gazette

LA = *Legislation Act 2003*

LIA = *Legislative Instruments Act 2003*

(md) = misdescribed amendment can be given effect

(md not incorp) = misdescribed amendment cannot be given effect

mod = modified/modification

No. = Number(s)

Ord = Ordinance

orig = original

p = page(s)

para = paragraph(s)/subparagraph(s) /sub-subparagraph(s)

pres = present

prev = previous

(prev…) = previously

pt = Part(s)

r = regulation(s)/Court rule(s)

reloc = relocated

renum = renumbered

rep = repealed

rs = repealed and substituted

s = section(s)/subsection(s) /rule(s)/subrule(s)/order(s)/suborder(s)

sch = Schedule(s)

SLI = Select Legislative Instrument

SR = Statutory Rules

sub ch = Sub-Chapter(s)

sub div = Subdivision(s)

sub pt = Subpart(s)

underlining = whole or part not commenced or to be commenced

Authorised Version F2026C00359 registered 24/04/2026

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Minimum Stockholding) Determination 2023 (PB 65 of 2023)	30 June 2023 (F2023L00919)	1 July 2023 (s 2(1) item 1)	
National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023 (PB 103 of 2023)	29 Sept 2023 (F2023L01338)	1 Oct 2023 (s 2(1) item 1)	—
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023 (PB 111 of 2023)	31 Oct 2023 (F2023L01455)	1 Nov 2023 (s 2(1) item 1)	—
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023 (PB 125 of 2023)	30 Nov 2023 (F2023L01573)	1 Dec 2023 (s 2(1) item 1)	—
National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 (PB 136 of 2023)	18 Dec 2023 (F2023L01702)	sch 2: 1 Feb 2024 (s 2(1) item 3) sch 3: 1 Apr 2024 (s 2(1) item 4) Remainder: 1 Jan 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024 (PB 10 of 2024)	31 Jan 2024 (F2024L00114)	sch 2: 1 June 2024 (s 2(1) item 3) Remainder: 1 Feb 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024 (PB 24 of 2024)	29 Feb 2024 (F2024L00228)	1 Mar 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024 (PB 32 of 2024)	28 Mar 2024 (F2024L00411)	1 Apr 2024 (s 2(1) items 1, 2, 3)	—
National Health (Minimum Stockholding) Amendment Determination (No.4) 2024 (PB 49 of 2024)	30 Apr 2024 (F2024L00502)	sch 2: 1 Oct 2024 (s 2(1) item 3) Remainder: 1 May 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 5) 2024 (PB 61 of 2024)	30 May 2024 (F2024L00591)	1 June 2024 (s 2(1) items 1, 2)	—

Authorised Version F2026C00359 registered 24/04/2026

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024 (PB 75 of 2024)	28 June 2024 (F2024L00809)	sch 2: 1 Oct 2024 (s 2(1) item 3) sch 3: 1 Dec 2024 (s 2(1) item 4) Remainder: 1 July 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024 (PB 83 of 2024)	31 July 2024 (F2024L00942)	1 Aug 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 8) 2024 (PB 90 of 2024)	28 Aug 2024 (F2024L01065)	1 Sept 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024 (PB 102 of 2024)	27 Sept 2024 (F2024L01234)	sch 3: 1 Dec 2024 (s 2(1) item 4) Remainder: 1 Oct 2024 (s 2(1) items 1-3)	—
National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024 (PB 121 of 2024)	30 Oct 2024 (F2024L01383)	sch 2: 1 Apr 2025 (s 2(1) item 3) Remainder: 1 Nov 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024 (PB 135 of 2024)	29 Nov 2024 (F2024L01521)	1 Dec 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 12) 2024 (PB 145 of 2024)	20 Dec 2024 (F2024L01746)	sch 2, 3: 1 Apr 2025 (s 2(1) items 3, 4 (first occurring)) sch 4: 1 June 2025 (s 2(1) item 4 (second occurring)) Remainder: 1 Jan 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 1) 2025 (PB 11 of 2025)	29 Jan 2025 (F2025L00053)	sch 2, 3: 1 Apr 2025 (s 2(1) items 3, 4) Remainder: 1 Feb 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025 (PB 22 of 2025)	27 Feb 2025 (F2025L00213)	sch 1: 1 Mar 2025 (s 2(1) item 2) sch 2: 1 Aug 2025 (s 2(1) item 3)	—
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2025 (PB 36 of 2025)	27 Mar 2025 (F2025L00443)	sch 2: 1 Oct 2025 (s 2(1) item 3) Remainder: 1 Apr 2025 (s 2(1) items 1, 2)	—

Authorised Version F2026C00359 registered 24/04/2026

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025 (PB 47 of 2025)	22 Apr 2025 (F2025L00520)	sch 2: 1 Oct 2025 (s 2(1) item 3) Remainder: 1 May 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025 (PB 64 of 2025)	28 May 2025 (F2025L00605)	sch 2: 1 Nov 2025 (s 2(1) item 3) Remainder: 1 June 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025 (PB 82 of 2025)	26 June 2025 (F2025L00755)	sch 2: 1 Oct 2025 (s 2(1) item 3) Remainder: 1 July 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 7) 2025 (PB 93 of 2025)	30 July 2025 (F2025L00886)	sch 3: 1 Oct 2025 (s 2(1) item 4) Remainder: 1 Aug 2025 (s 2(1) items 1-3)	—
National Health (Minimum Stockholding) Amendment Determination (No. 8) 2025 (PB 101 of 2025)	28 Aug 2025 (F2025L01000)	sch 2: 1 Oct 2025 (s 2(1) item 3) Remainder: 1 Sept 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 9) 2025 (PB 118 of 2025)	29 Sept 2025 (F2025L01183)	sch 4: 1 Nov 2025 (s 2(1) item 5) Remainder: 1 Oct 2025 (s 2(1) items 1-4)	—
National Health (Minimum Stockholding) Amendment Determination (No. 10) 2025 (PB 130 of 2025)	30 Oct 2025 (F2025L01310)	sch 2: 1 Apr 2026 (s 2(1) item 3) Remainder: 1 Nov 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 11) 2025 (PB 148 of 2025)	26 Nov 2025 (F2025L01436)	1 Dec 2025 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 12) 2025 (PB 159 of 2025)	22 Dec 2025 (F2025L01625)	1 Jan 2026 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 1) 2026 (PB 9 of 2026)	27 Jan 2026 (F2026L00051)	sch 2: 1 Apr 2026 (s 2(1) item 3) sch 3: 1 June 2026 (s 2(1) item 4) Remainder: 1 Feb 2026 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2026 (PB 27 of 2026)	25 Feb 2026 (F2026L00156)	sch 2: 1 Aug 2026 (s 2(1) item 3) Remainder: 1 Mar 2026 (s 2(1) items 1, 2)	—

Authorised Version F2026C00359 registered 24/04/2026

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2026 (PB 39 of 2026)	26 Mar 2026 (F2026L00379)	sch 2: 1 Oct 2026 (s 2 (1) item 3) Remainder: 1 Apr 2026 (s 2(1) items 1, 2)	—

Authorised Version F2026C00359 registered 24/04/2026

Endnote 4—Amendment history

Provision affected	How affected
Part 1	
s 2.....	rep LA s 48D
s 5.....	am F2023L01338
Schedule 1	
Schedule 1.....	am F2023L01338
	rs F2023L01455
	am F2023L01455; F2023L01573
	ed C3
	am F2023L01702; F2024L00114
	ed C5
	am F2024L00228; F2024L00411; F2024L00502; F2024L00591; F2024L00809; F2024L00942
	ed C11
	am F2024L01065; F2024L00502 (sch 2 (item 4) md not incorp); F2024L00809; F2024L01234; F2024L01383; F2024L01521; F2024L01746; F2025L00053; F2025L00213 (sch 1 (item 27) md not incorp); F2025L00443; F2025L00520; F2025L00605; F2025L00755; F2025L00886; F2025L01000; F2025L01183; F2025L01310; F2025L01436; F2025L01625; F2026L00051 (sch 1 (item 14); sch 2 (item 1) md not incorp) (sch 3); F2026L00156 (sch 2); F2026L00379 (sch 2)

Authorised Version F2026C00359 registered 24/04/2026